Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 64

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 64
---
-votes will have the same effect as a vote AGAINST the proposal” |

Q.Why is NLS providing shareholders with the opportunity to vote on the Merger? Among other reasons, Swiss corporate law requires that shareholders approve certain significant corporate actions such as the issuance of merger compensation shares at a meeting of the NLS shareholders. Q.What is required to consummate the Merger? To consummate the Merger, Proposals Nos.1,2,4,6,8, 13 and 14 must be approved at the NLS Meeting, or at any permitted adjournment thereof, by the requisite holders of NLS Common Shares and Preferred Shares on the record date for the NLS Meeting. The Merger will not occur if Proposals Nos.1,2,4,6,8, 13 and 14 are not approved by NLS’s shareholders, unless NLS and Kadimastem agree to amend the Merger Agreement or waive certain closing conditions. In addition to the requirement of obtaining such shareholder approvals, each of the other closing conditions set forth in the Merger Agreement must be satisfied or waived. Q.What conditions must be satisfied or waived to complete the Merger? The Merger Agreement contains closing conditions that are customary for a transaction of this nature, including the requirement for approval by the shareholders of each of Kadimastem and NLS. Kadimastem has received approval of the Merger by its shareholders. In addition, the Merger Agreement requires NLS to have paid off, redeemed or satisfied all of its trade and vendor payables, and all of its debts to its officers, directors and shareholders. The Merger Agreement requires NLS to have at least $600,000 in cash at the Closing and requires Kadimastem to have at least $3,500,000 in cash at the Closing, in each case subject to adjustments as set forth in the Merger Agreement. Based on the proceeds received by NLS in connection with its financing transactions undertaken after the execution of the Merger Agreement, and in accordance with the adjustments as set forth in the Merger Agreement, Kadimastem satisfied the Investment Proceeds Adjustment and will therefore not be required to have cash at Closing. Neither NLS nor Kadimastem is required to make any filings or obtain any approvals or clearances from any antitrust regulatory authorities in the United States or other countries to consummate the Merger. In the United States, NLS must comply with applicable federal and state securities laws and Nasdaq